Csl112 drug
WebAug 7, 2024 · CSL112 or placebo was administered as a single 2 h i.v. infusion into a suitable peripheral or central vein. Pharmacokinetics and pharmacodynamics of apoA-I ApoA-I concentration was assessed by an immunonephelometric method run on Roche Modular P at a specialty lipid laboratory (Pacific Biomarkers). WebAug 25, 2015 · CSL112 is an investigational, reconstituted HDL product containing apoA‐I purified from human plasma and formulated with phosphatidylcholine. 22 Lyophilized CSL112 was reconstituted with …
Csl112 drug
Did you know?
WebMar 22, 2024 · Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) The safety and scientific validity of this study is the responsibility of the … WebThe CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2024 Feb;208:81-90. doi: 10.1016/j.ahj.2024.11.008. Epub 2024 Nov 22.
WebMar 30, 2024 · CSL112 (Human Apolipoprotein A-I) Infusion Rapidly Increases APOA1 (Apolipoprotein A1) Exchange Rate via Specific Serum Amyloid-Poor HDL (High-Density Lipoprotein) Subpopulations When Administered to Patients Post–Myocardial Infarction Arteriosclerosis, Thrombosis, and Vascular Biology
WebI joined CSL in 2009 and worked in Translational Science on several drugs in development including CSL112 HDL infusion therapy and antiVEGFB CSL346. In 2024 I moved to … WebJan 14, 2024 · CSL 112 - AdisInsight Drug Profile CSL 112 Alternative Names: ApoA-1; Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; CSL112 apo-AI; rHDL - CSL Latest Information Update: 14 Jan 2024 Price : $50 * Buy Profile Adis is an information provider. We do not sell or distribute actual drugs.
WebCSL112 (apolipoprotein A-I [apoA-I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC).
WebCSL112 is a formulation of a naturally occurring protein called apolipoprotein A1, or apoA-I which regulates the process that flushes cholesterol out of the arteries and to the liver, … kotdwar to rishikesh distanceWebYou received your blood test result with a Cholesterol value of 112 mg/dL. This analysis helps you to check if your Cholesterol value is within normal range. Cholesterol 0 … kotdwar to jim corbett national parkWebMar 26, 2024 · “CSL112 is an exciting new approach in cardiovascular medicine that may help protect our patients when they are most vulnerable.” Research showed that … manorcare health services sarasota flWebCSL112 may offer a new approach for rapidly stabilizing atherosclerotic plaque lesions and is being developed for reduction in the risk of early cardiovascular … manorcare health services-york southWebJun 26, 2014 · In the single ascending dose (SAD) study, 58 subjects were randomized to receive CSL112 or placebo in a 3:1 ratio, 57 received a dose of study drug, and 56 completed the study. One subject was withdrawn before dose administration and another was withdrawn after dose administration because of an adverse event. kotdwar stationWebFeb 14, 2024 · CSL Behring’s landmark AEGIS-II Phase 3 trial investigating CSL112 is the largest trial ever undertaken by our company and is the embodiment of our patient-first … manorcare health services veniceWebCSL112 is a reconstituted, infusible human plasma-derived apolipoprotein A-I (apoA-I) that increases cholesterol efflux capacity – an ex vivo measure of the ability of HDL to accept cholesterol from macrophages. Areas covered: This article reviews the pharmacology of CSL112 and its current clinical development status. manorcare health services sarasota